Innovation
in Nucleic Acid Therapeutics for Human Health

History

  • HOME
  • About OliX
  • History
  • 2019
    Apr. [OLX201] Candidate substance for the treatment of Idiopathic Pulmonary Fibrosis patented in the US
    Mar. [OLX301A] Collaboration and License Agreement with Théa Open Innovation for the treatment of AMD
    Feb. Establishment of OliX San Diego R&D Lab
    Feb. [OLX103] Candidate substance for the treatment of Atopic Dermatitis patented in the US
    Jan. [OLX031A] Clinical Candidate Nomination for the Treatment of Geographic Atrophy
  • 2018
    Nov. Compound for increasing siRNA and RNA interference effects patented in Korea
    Nov. [OLX101] Candidate substance for the treatment of hypertrophic scarring patented in Europe
    Nov. [OLX101] Phase 2 clinical trial approved in Korea for candidate substance for the treatment of hypertrophic scarring
    Oct. 'A phase 1 study of OLX10010, a potential treatment for hypertriphic scar, using a self-delivering RNAi compound' was selected as a KOREA Drug Development Fund project
    Oct. Established OliX US Inc.
    Jul. Listed on the KOSDAQ
    Jul. [OLX301A] Candidate substance for the treatment for age-related macular degeneration patented in US
    May. [OLX101] CTA approval of phase 1 clinical trial for OLX10010 (candidate substance for the treatment of hypertrophic scarring) in the UK (MHRA)
    May. [OLX101] Completion of phase 1 clinical trial for OLX10010 (candidate substance for the treatment of hypertrophic scarring) in Korea
  • 2017
    Oct. Passed the technology evaluation (A, A) for IPO
    Jun. Sr. VP received an KFDA award
    May. Asymmetric lasiRNA platform patented in the US
    Feb. Opened the Nucleic Acid Eye Center
    Jan. [OLX101] Phase 1 clinical trial approved in Korea for candidate substance for the treatment of hypertrophic scarring
    Jan. Moved to new company location in Suwon
  • 2016
    Dec. CEO recognized by the Minister of Health & Welfare Award
    Jul. [OLX101] Published hypertrophic scarring therapeutics data in Journal of Investigative Dermatology
    Apr. Completed Series B funding
    Mar. [OLX102] Listed a skin whitening substance on ICID
  • 2015
    Jul. Certified as Technology Innovative Small to Medium Enterprise (INNO-BIZ)
    Jun. Raised strategic investment (Hugel)
    Apr. 'Development of RNA interference based atopic dermatitis treatment' was selected as a Technology Development Support Project (KOREA Small and Medium Business Administration)
  • 2014
    Nov. 'Pre-clinical and clinical study of anti-scarring therapeutics BMT101, self-delivering RNAi molecule.' was selected as a KOREA Drug Development Fund project
    Oct. Changed company name to OliX, Inc.
    Sep. 'Therapeutics development for Idiopathic Pulmonary Fibrosis using BMT101, a pre-validated oligonucleotide drug inhibiting fibrosis' was selected as a Korea-Singapore R&D project (Ministry of Health and Welfare)
    Aug. Completed Series A funding
  • 2013
    Nov. [OLX101] Collaboration and License Agreement with Hugel Inc. for the treatment of hypertrophic scarring
    May. Filed a patent application for cp-asiRNA platform
    Feb. Angel investment raised
  • 2012
    Nov. Moved to Gasan Digital Complex
    May. Filed a patent application for cp-asiRNA platform
  • 2011
    Dec. Initiated cp-asiRNA platform development
    Oct. Company affiliated research center certified
    Jun. Obtained an exclusive license for asymmetric lasiRNA
  • 2010
    Sep. Certified as a venture company (Kibo Technology Fund)
    Mar. Obtained an exclusive license for asymmetric siRNA
    Feb. Established BMT, Inc.

LOGO DESIGN